Difference between revisions of "Rumoured Buzz Concerning ZD1839"
(Created page with "The correct author names are as shown above. ""Airway remodeling contributes to increased mortality in asthma. We have reported that triptolide can inhibit airway remodeling i...")
Latest revision as of 15:22, 4 December 2019
The correct author names are as shown above. ""Airway remodeling contributes to increased mortality in asthma. We have reported that triptolide can inhibit airway remodeling in a mouse asthma model. In this study, we aimed to investigate the effect of triptolide on airway smooth muscle cells (ASMCs) proliferation, migration and the possible mechanism. Rat airway smooth muscle cells were cultured and made synchronized, then pretreated with different concentrations of triptolide before stimulated by TGF-��1. Cell proliferation was evaluated by cell counting and ZD1839 MTT assay. Flow cytometry was used to study the influence of triptolide on cell cycle. Migration was measured by Transwell analysis. Signal proteins (NF-��B p65 and ERK1/2) were detected by western blotting analysis. LDH releasing test and flow cytometry analysis of apoptosis were also performed to explore the potential cytotoxic or pro-apoptotic effects of triptolide. Triptolide significantly inhibited TGF-��1 induced ASMC proliferation and migration (pAZD6738 cost was blocked at G1/S-interphase by triptolide dose dependently. Western blotting analysis showed TGF-��1 induced NF-��B p65 phosphorylation was inhibited by triptolide pretreatment, but ERK1/2 was not affected. No cytotoxic or pro-apoptotic effects were detected under the concentration of triptolide we used. Triptolide may function as an inhibitor of asthma airway remodeling by suppressing ASMCs proliferation and migration through inactivation of NF-��B pathway. This article is protected by copyright. All rights reserved. ""The ability of skin antimicrobial peptides of the southern bell frog, Litoria raniformis, to neutralize in vitro the endotoxin, proinflammatory lipopolysaccharide (LPS) complex, from two different gram-negative bacterial pathogens, human pathogen Escherichia coli (0111:B4) and frog pathogen Klebsiella pneumoniae, was investigated. The LPS neutralization activity of the natural mixture of skin antimicrobial peptides was measured using chromogenic Limulus amebocyte lysate assays. These skin antimicrobial peptides neutralized the LPSs from both pathogens at physiologically relevant concentrations Crizotinib (IC50?